article thumbnail

Young Pharmaceuticals Opens New Global Headquarters

MedEsthetics

young pharmaceuticals, global expansion, new global headquarters, John Kulesza, skin care products, skin care, business, business expansion, medical aesthetics, dermatologic products

article thumbnail

Get to Know Alys Pharmaceuticals, Inc.

The Dermatology Digest

Alys Pharmaceuticals, Inc. Alys combines six asset-centric Medicxi companies including Al Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics. ” The post Get to Know Alys Pharmaceuticals, Inc. appeared first on The Dermatology Digest.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

LEO Pharma to Acquire Timber Pharmaceuticals

Dermatology Times

Timber Pharmaceuticals has been developing TMB-001 for the treatment of congenital ichthyosis.

article thumbnail

LEO Pharma Completes Key Asset Acquisition, Including TMB-001, From Timber Pharmaceuticals

Dermatology Times

The finalized acquisition comes 5 months after Timber Pharmaceuticals filed for chapter 11 bankruptcy.

article thumbnail

Verrica Pharmaceuticals’ YCANTH Receives New Chemical Entity Status, Orange Book Listing From FDA

The Dermatology Digest

Verrica Pharmaceuticals Inc.’s The post Verrica Pharmaceuticals’ YCANTH Receives New Chemical Entity Status, Orange Book Listing From FDA appeared first on The Dermatology Digest. s YCANTH now has New Chemical Entity (NCE) Status and a listing in the Orange Book from the U.S. YCANTH (cantharidin) topical solution, 0.7%

article thumbnail

Ligand Pharmaceuticals Launches Pelthos to Accelerate Commercialization of Zelsuvmi for Molluscum; Appoints New CEO

The Dermatology Digest

Ligand Pharmaceuticals is launching Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and has appointed Scott Plesha as Chief Executive Officer to accelerate the commercialization of berdazimer topical gel, 10.3% (Zelsuvmi) for the treatment of molluscum contagiosum. in September 2023.

article thumbnail

Done Deal: LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals 

The Dermatology Digest

LEO Pharma now owns TMB-001 as well as certain other assets from Timber Pharmaceuticals following its chapter 11 bankruptcy filing. All employees of Timber Pharmaceuticals will transition to LEO Pharma’s offices in New Jersey, US, the Company reports. The TMB-001 project continues as planned and without changes within LEO Pharma.